Fibroblast growth factor receptor (
Antineoplastic Agents
/ therapeutic use
Biomarkers, Tumor
/ genetics
Carcinoma
/ drug therapy
Exons
Gene Amplification
Gene Fusion
Genetic Predisposition to Disease
Humans
Molecular Targeted Therapy
Mutation, Missense
Phenotype
Phenylurea Compounds
/ therapeutic use
Piperazines
/ therapeutic use
Protein Kinase Inhibitors
/ therapeutic use
Pyrazoles
/ therapeutic use
Pyrimidines
/ therapeutic use
Pyrroles
/ therapeutic use
Quinoxalines
/ therapeutic use
Receptor, Fibroblast Growth Factor, Type 3
/ antagonists & inhibitors
Thiophenes
/ therapeutic use
Urinary Bladder Neoplasms
/ drug therapy
Urothelium
/ pathology
diagnosis
male urogenital diseases
molecular
pathology
urologic diseases
urologic neoplasms
Journal
Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
15
09
2020
revised:
12
11
2020
accepted:
24
01
2021
pubmed:
19
3
2021
medline:
3
8
2021
entrez:
18
3
2021
Statut:
ppublish
Résumé
Dysregulation of fibroblast growth factor receptors (
Identifiants
pubmed: 33731335
pii: jclinpath-2020-207115
doi: 10.1136/jclinpath-2020-207115
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Phenylurea Compounds
0
Piperazines
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
Pyrroles
0
Quinoxalines
0
Thiophenes
0
erdafitinib
890E37NHMV
Rogaratinib
98BSN6N516
infigratinib
A4055ME1VK
FGFR3 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 3
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
491-495Informations de copyright
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.